COMMUNIQUÉS West-GlobeNewswire

-
NetraMark Completes 2025 Annual General Meeting
10/06/2025 -
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/06/2025 -
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
10/06/2025 -
myLAB Box Announces Official Website Update Featuring At-Home Wellness Testing Services
10/06/2025 -
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
10/06/2025 -
BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)
10/06/2025 -
ReflexMD Expands Digital Health Access Nationwide with Seamless Prescription Experience
10/06/2025 -
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
11/06/2025 -
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
11/06/2025 -
Enhance.MD Launches Nationwide Telehealth Expansion to Support Men’s Hormonal Health and Medically Supervised Weight Loss
11/06/2025 -
PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors
11/06/2025 -
Cooper Aerobics Partners with Parker University
11/06/2025 -
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
11/06/2025 -
Mochi Health Launches Enhanced Online Platform to Support Medical Weight Loss Patients Nationwide
11/06/2025 -
NuggMD Now Serves All Eligible Medical Cannabis Patients Nationwide via Secure Telehealth Platform
11/06/2025 -
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
10/06/2025 -
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
10/06/2025 -
PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support
10/06/2025 -
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense
10/06/2025
Pages